+ Watch ACHN
on My Watchlist
A biopharmaceutical company focuses on the discovery, development and commercialization of innovative treatments for infectious diseases
sometimes you need to act first and think about it later. ACHN falls into that category in the IDIX news today. added ACHN to the RL fund at 6.14 funded by some sales of homebuilder MDC. While the IDIX selling seems overdone I think the ACHN buying in the news should be a bit stronger. Still a competitive field and these guys aren't exactly a market leader. While I dig deeper into this decision I hope that the Momentum stays in my favor... : )
Let's not overthink this...market cap is 1/2 of what it was in January when buyout speculation was rampant. Now we have an entire class of competitive HCV drugs under extreme pressure who were previously well ahead of ACHN's game early this year. Big Pharma doesn't want to get burned again but they won't be able to resist getting boxed out. ACHN has a winning hand but it is weak so they will sell for a win-win at 10 bucks. : )
My price target is approaching...sooner than expected!
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions